MNPR
HealthcareMonopar Therapeutics Inc.
$61.73
$-4.28 (-6.48%)
Jan 5, 2026
Price History (1Y)
Analysis
Monopar Therapeutics Inc. is a biotechnology company operating within the healthcare sector. With a market capitalization of $412.52M, it falls into the category of small-cap companies in its industry. The financial health of Monopar Therapeutics Inc. indicates significant losses, with a net income of -$19,441,708 over the last four quarters. The company's margins are at 0.0% for both gross and operating profit margins, and a 0.0% profit margin. Returns on equity and assets stand at -26.5% and -18.0%, respectively. On its balance sheet, Monopar has $143.68M in cash and $102,236 in debt, resulting in a debt-to-equity ratio of 0.07. Monopar Therapeutics Inc.'s valuation is marked by a negative forward price-to-earnings ratio of -17.89 and a price to book value of 2.91. The company's beta is 1.47, indicating a relatively higher volatility compared to the market average.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Monopar Therapeutics Inc.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Visit website →Key Statistics
- Market Cap
- $412.52M
- P/E Ratio
- N/A
- 52-Week High
- $105.00
- 52-Week Low
- $23.00
- Avg Volume
- 181.23K
- Beta
- 1.47
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 14